Podcasts about ATR

Have you put yourself aside for years? In this episode, I talk with Jen Berlingo, LPC, ATR about tuning back into your inner calling and… • Emerging in midlife and unmasking to be your full self again  • Looking inward to identify what needs to change • Navigating big life changes and taking one small step forward at a time • Turning your ear back inward to listen to your inner yearnings and reclaiming your true nature • Assessing whether your lifestyle supports your sensitive nervous system  • Learning to assert your preferences in a world that's not built for HSPs  • Stop abandoning yourself and people pleasing to make others comfortable  Jen (she/her) is a midlife coach, a Licensed Professional Counselor, a Nationally Registered Art Therapist, and a master-level Reiki practitioner. After two decades of midwifing hundreds of women through life's major transitions and experiencing her own passage through a fiery midlife portal where she more fully stepped into her queer identity, she was inspired to write Midlife Emergence to accompany other women in traversing their midlife journeys. Upon its publication, Midlife Emergence reached #1 in several Amazon categories, including midlife management, divorce, LGBTQ+ memoirs, LGBTQ+ parenting and families, adulthood and aging, and self-help. Jen is also a visual artist who not only created the painting on the cover of her book, but also makes custom pieces for collectors worldwide and exhibits her fluid, abstract art locally in her beloved town of Boulder, Colorado.  Keep in touch with Jen: • Website: https://jenberlingo.com • Substack: https://jenberlingo.substack.com  • Instagram: https://www.instagram.com/jenberlingo   • Facebook: https://www.facebook.com/jenberlingotherapy  • Etsy Shop: https://www.etsy.com/shop/artsorceress  Additional Resources: • Get support when undergoing profound transitions like midlife, divorce, or coming out later in life. Learn more + sign up for a free discovery call with Jen at https://jenberlingo.com/coaching  • Midlife Emergence Book: https://jenberlingo.com/book  • 100 Day Project: Thanks for listening! You can read the full show notes and sign up for my email list to get new episode announcements and other resources at: https://www.sensitivestories.comYou can also follow "SensitiveStrengths" for behind-the-scenes content plus more educational and inspirational HSP resources: Instagram: https://www.instagram.com/sensitivestrengths TikTok: https://www.tiktok.com/@sensitivestrengths Youtube: https://www.youtube.com/@sensitivestrengths And for more support, attend a Sensitive Sessions monthly workshop: https://www.sensitivesessions.com. Use code PODCAST for 25% off. If you have a moment, please rate and review the podcast, it helps Sensitive Stories reach more HSPs! This episode is for educational purposes only and is not intended as a substitute for treatment with a mental health or medical professional. Some links are affiliate links. You are under no obligation to purchase any book, product or service. I am not responsible for the quality or satisfaction of any purchase.

Atrévete (Tramo de 07:00 a 08:00)

Atrévete (Tramo de 09:00 a 10:00)

Atrévete (Tramo de 10:00 a 11:00)

Atrévete (Tramo de 06:00 a 07:00)

Atrévete (Tramo de 08:00 a 09:00)

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.In a dynamic landscape marked by both advancements and challenges, the pharmaceutical and biotech sectors continue to evolve with notable scientific, regulatory, and strategic updates. Ipsen's recent $1 billion acquisition of Simcere's preclinical LRRC15-targeting asset underscores a growing focus on antibody-drug conjugates (ADCs). These conjugates leverage the targeted action of antibodies combined with the cytotoxic effects of drugs, representing a promising approach to cancer treatment by potentially minimizing systemic toxicity. Ipsen's strategic move reflects its commitment to expanding its oncology portfolio and staying competitive within the rapidly advancing ADC landscape.AstraZeneca has been active in its pursuit of innovative cancer treatments. The company has invested $100 million in Jacobio's clinical-stage pan-KRAS inhibitor, a promising development targeting KRAS mutations prevalent in various cancers. This investment aligns with AstraZeneca's strategy to tackle challenging oncogenic targets. However, their efforts faced a setback as their Phase 3 trial for ceralasertib, an ATR inhibitor for lung cancer, failed to meet its primary endpoint. Despite this setback, AstraZeneca maintains confidence by investing significantly in promising areas like KRAS inhibitors, highlighting the inherent risks involved in pioneering novel therapeutic strategies, particularly those aiming to overcome resistance mechanisms in immuno-oncology.BioMarin has quietly discontinued its liver disease candidate amid a $4.8 billion deal with Amicus. This decision points to the complex nature of pipeline prioritization and resource allocation within high-stakes financial environments. The company's strategic shifts reflect ongoing evaluations of their development priorities in light of evolving market demands.Boehringer Ingelheim has demonstrated a commitment to renal therapeutics with a $448 million investment in Rectify Pharmaceuticals for a preclinical chronic kidney disease program. This partnership seeks to address significant unmet medical needs within kidney disease treatment. Meanwhile, Gilead Sciences has entered into a $35 million licensing agreement with Assembly Biosciences for herpes simplex virus (HSV) assets, diversifying its infectious disease portfolio and expanding its reach within antiviral therapies.Novo Holdings-backed Windward Bio's acquisition of rights to Qyun's clinical-stage immunology bispecifics for $700 million highlights robust activity in the immunology space. Bispecific antibodies are gaining traction due to their ability to target two antigens simultaneously, offering enhanced therapeutic efficacy. This acquisition illustrates ongoing interest in this area as companies seek innovative solutions to complex immunological challenges.The broader industry is also witnessing strategic partnerships such as Aditum Bio's launch of a new biotech venture with Fosun Pharma. This collaboration aims to foster novel therapies through a synergistic blend of biotechnology innovation and pharmaceutical expertise. These alliances reflect an industry trend towards collaborative efforts that leverage diverse strengths to advance therapeutic development.In regulatory news, nine major pharmaceutical companies have reached agreements with the U.S. government to lower certain drug prices in exchange for tariff relief. This development signals ongoing negotiations aimed at balancing drug affordability with industry sustainability amid growing scrutiny over pricing practices.In December 2025, significant developments emerged, impacting scientific innovation, regulatory approvals, mergers, and strategic partnerships across the industry. Notably, the U.S. Food and Drug Administration (FDA) granted early approval to Cytokinetics' MyqorzSupport the show

Atrévete (Tramo de 08:00 a 09:00)

Atrévete (Tramo de 09:00 a 10:00)

Atrévete (Tramo de 07:00 a 08:00)

Atrévete (Tramo de 06:00 a 07:00)

Atrévete (Tramo de 10:00 a 11:00)

No episódio de hoje do BBcast Agro, Fabíola Lira, assessora de agronegócios do Banco do Brasil em Tangará da Serra-MT, analisa o encerramento da safra no centro-sul, os impactos das chuvas no nordeste e a mudança no mix de produção das usinas.Destaques do episódio:

Atrévete (Tramo de 06:00 a 07:00)

Atrévete (Tramo de 07:00 a 08:00)

Atrévete (Tramo de 08:00 a 09:00)

Atrévete (Tramo de 09:00 a 10:00)

Atrévete (Tramo de 10:00 a 11:00)

¿Quieres descubrir cómo tener el poder para lograr lo que quieres?: En un mundo donde la manipulación es una herramienta cotidiana, la inocencia es similar a la ignorancia. ¿Estás preparado para identificar y defenderte de las tácticas de poder que otros usan en tu contra? Este libro no es una guía sobre ética o buenas intenciones. Es un manual amoral, despiadado y, sobre todo, muy instructivo que destila tres mil años de historia en 48 leyes claras y concisas sobre cómo obtener, estudiar y combatir el poder absoluto. No es una invitación a convertirte en un tirano, sino una herramienta esencial para comprender cómo operan tus enemigos y colegas y reconocer sus acciones maliciosas. Inspirado en las mentes de Maquiavelo y Sun Tzu, aprenderás a: Nunca hacerle sombra a tu superior, siendo invaluable sin ser percibido como una amenaza. Aplastar por completo a tu enemigo para que no pueda volver a desafiarte. Disimular tus intenciones y mantener a todos desinformados. Reconocer y protegerte de la “Tríada Oscura” de la personalidad: líderes narcisistas, maquiavélicos y psicópatas. El poder transforma. Si no estás dispuesto a entender sus reglas, te arriesgas a ser víctima de ellas. Atrévete a descubrir la cruda verdad y aprende a jugar el juego que todos juegan, lo admitan o no.

Atrévete (Tramo de 07:00 a 08:00)

Atrévete (Tramo de 08:00 a 09:00)

Atrévete (Tramo de 09:00 a 10:00)

Atrévete (Tramo de 09:00 a 10:00)

Atrévete (Tramo de 08:00 a 09:00)

Atrévete (Tramo de 07:00 a 08:00)

Atrévete (Tramo de 06:00 a 07:00)

Atrévete (Tramo de 10:00 a 11:00)

Are you looking to save time, make money, and start winning with less risk? Then head to https://www.ovtlyr.com.It was one of those market days that makes people panic. Big red candles, ugly price action, and nonstop noise about what is “supposed” to happen next. But this video is about why those days do not need to control your emotions, your decisions, or your account when you actually have a plan.This session walks through what separates reactive traders from disciplined ones. When the market is down hard, most people feel pressure to act, predict, or fix something. What you see here is a very different approach. Instead of guessing bottoms or averaging down blindly, the focus stays on trend structure, signals, expectancy, and risk control. When you know exactly what you are waiting for, the stress drops dramatically and the decision-making becomes simple.A big theme in this video is psychology. Watching price move without a framework feels chaotic. Once you understand trends, EMAs, ATR, and why exits matter just as much as entries, the market stops feeling random. You do not need to stare at charts all day. You do not need to babysit positions. You just follow the plan and let the data do the heavy lifting.There is also a deep dive into why prediction-based trading fails so many people. Doubling down, hoping, or assuming something has to bounce eventually sounds logical until you realize you never know how far a move can go. This video breaks down why waiting for confirmation puts you in profitable trends faster, with less time underwater and far less emotional damage.Midway through, the discussion shifts into real backtesting data. This is where things get interesting. Instead of “trust me” opinions, you see how expectancy, win rate, ATR behavior, and Monte Carlo testing actually work together. You also learn why some sectors are avoided completely, even if they look tempting, and how frequency and risk-adjusted returns matter more than chasing home runs.Key ideas covered in this video include:✅ Why red days are only scary when you do not have a plan✅ How trend signals remove emotion from trading decisions✅ The role of ATR in defining risk, exits, and expectations✅ Why random trade selection can still work when expectancy is positive✅ How V-shaped recoveries waste time compared to trend confirmationThe bigger takeaway is simple. Trading does not have to be stressful, dramatic, or chaotic. When your rules are clear and tested, you already know what you will do before price ever moves. That clarity is what allows traders using the OVTLYR approach to stay calm while everyone else is freaking out.If you want a calmer, more repeatable way to approach the market that is grounded in data instead of hype, this video is worth your time.Gain instant access to the AI-powered tools and behavioral insights top traders use to spot big moves before the crowd. Start trading smarter today

Atrévete (Tramo de 10:00 a 11:00)

Atrévete (Tramo de 07:00 a 08:00)

Atrévete (Tramo de 06:00 a 07:00)

Atrévete (Tramo de 08:00 a 09:00)

Atrévete (Tramo de 09:00 a 10:00)

  «Pero cuando se manifestó la bondad de Dios, nuestro Salvador, y su amor para con los hombres... el cual derramó en nosotros abundantemente por Jesucristo, nuestro Salvador, para que al ser justificados por su gracia viniéramos a ser herederos conforme a la esperanza de la vida eterna» (Tito 3:4,6-7) Un pacto de gracia. Eso es lo que nosotros tenemos con el Dios todopoderoso. Si en realidad entendieras la importancia                                                                                                                                            de este pacto, nunca más serías el mismo. ¿De qué se trata exactamente ese pacto de gracia? Es una relación de favor que te da acceso al poder de otra persona. Una ilustración del pacto de gracia es el pacto que los miembros de las antiguas familias sicilianas tenían con el "padrino" de la "familia". En ese clan, una persona en una situación de desventaja podía pedirle al padrino un favor. El padrino decía: «Te concederé este favor y a cambio te pediré otro. Llegado el momento oportuno, te haré saber cuál será ese favor». Una vez que el padrino decía esas palabras, la persona en desventaja se llenaba de emoción. De repente, sabía que se había quitado un gran peso de encima. Si alguien trataba de causarle problemas, ese alguien tendría que entenderse con el padrino, quien ejercía todo el poder. La actitud de la persona en desventaja cambiaba por completo; salía de la presencia del jefe de la familia con la confianza plena de que no tenía de qué preocuparse. Ya no se veía a sí mismo en su mente pequeño y sin poder. Había obtenido favor (o gracia) con el poderoso. Esa persona se iba pensando: "Todo está arreglado. Sólo debo cumplir lo que el padrino me pida―y él sabe que no tengo nada; así que cualquier cosa que me pida que haga, él proveerá los medios para hacerlo". Eso es gracia: la voluntad de Dios para establecer un pacto de sangre con nosotros mediante el cual nos da todo lo que Él tiene a cambio de todo lo que nosotros tenemos. Él tomó nuestro pecado para entregarnos a cambio Su justicia. Tomó nuestras enfermedades para darnos Su salud. Él tomó nuestra pobreza para suplir todo lo que necesitamos conforme a Sus riquezas en gloria. Siempre que Dios nos pide que hagamos algo, Él pone a nuestro alcance todo lo que necesitamos para hacerlo. El gran Jehová, el Dios del cielo y de la Tierra, es nuestro Padre Dios. ¿Comprendes lo que eso significa? Si estás cubierto por la sangre de Jesús, has sido hecho un hijo de pacto del Ser más poderoso del universo. ¡Atrévete a ocupar tu lugar en la familia! Lectura bíblica: Lucas 4:14-21   © 1997 – 2019 Eagle Mountain International Church Inc., también conocida como Ministerios Kenneth Copeland / Kenneth Copeland Ministries. Todos los derechos reservados.

Are you looking to save time, make money, and start winning with less risk? Then head to https://www.ovtlyr.com.If you've ever wondered why so many options traders blow up their accounts, this video breaks it all down in a way that actually makes sense. The reality is uncomfortable but important. Roughly 90 percent of options traders lose money, not because they're stupid, but because they're trading without a real framework, without position sizing, and without understanding how risk actually works.This walkthrough digs into the real reasons traders fail and what separates disciplined traders from people just chasing screenshots on social media. You'll hear honest explanations about leverage, capital efficiency, psychology, and why getting lucky early can actually be one of the most dangerous things that happens to a trader.Instead of hype or shortcuts, the focus stays on what actually matters long term. Risk per trade. Position sizing using ATR. Why deep in-the-money options can dramatically change the math. Why blowing up an account is common, but not inevitable. And why trading without a plan turns even a high win rate into a losing strategy.There's also a real-world breakdown of how traders get trapped by probability metrics, earnings volatility, and false confidence. The Palantir example alone is a masterclass in how “high probability” trades can still wipe you out if you don't understand context, expected moves, and event risk.Midway through the video, things get practical fast. You'll see exactly how the same dollar risk can be applied across wildly different stocks, from slow movers to high-flyers, without gambling the entire account. This is where capital efficiency becomes a weapon instead of a liability.Here's what you'll walk away with:✅ Why most traders lose money even with “good” strategies✅ How proper position sizing keeps losses survivable✅ The real role of ATR in defining risk, not profit✅ Why deep in-the-money options change the leverage equation✅ How emotions quietly destroy accounts without traders noticingThe conversation also gets brutally honest about discipline. Cutting losers. Avoiding FOMO. Not doubling down out of hope. Following a predefined plan even when it feels uncomfortable. This isn't about winning every trade. It's about staying in the game long enough for an edge to actually work.If you're serious about trading, this isn't motivational fluff. It's a reality check paired with a framework that prioritizes survival first, consistency second, and growth last. That mindset shift alone can be the difference between blowing up and building something sustainable.This video is especially valuable if you're new to options, transitioning from paper trading, or struggling to understand why your results don't match your win rate. It connects the dots between math, psychology, and execution in a way most trading content avoids.Watch it all the way through, take notes, and revisit the sections on risk and position sizing. These concepts compound over time, just like bad habits do if they're ignored.Gain instant access to the AI-powered tools and behavioral insights top traders use to spot big moves before the crowd. Start trading smarter today

Atrévete (Tramo de 07:00 a 08:00)

Atrévete (Tramo de 06:00 a 07:00)

Atrévete (Tramo de 08:00 a 09:00)

Atrévete (Tramo de 09:00 a 10:00)

Atrévete (Tramo de 10:00 a 11:00)

Welcome to Ozempic Weightloss Unlocked, the show that unpacks how these medicines are reshaping health, lifestyle, and the science of weight loss.Ozempic is the brand name for semaglutide, a glucagon like peptide one medicine originally approved for type two diabetes that also leads to significant weight reduction. Clinical trials like the STEP program, published in journals such as The New England Journal of Medicine and summarized by the journal Obesity, show average weight loss around fifteen percent of body weight over a little more than a year when combined with lifestyle changes.Real world reports collected by MedShadow describe how some people see dramatic improvements in blood sugar, blood pressure, and joint pain, while others struggle with nausea, constipation, heartburn, or even mood changes. One long term study cited by MedShadow found that people who stopped semaglutide regained about seventy percent of the weight they had lost, highlighting that this often works best as a long term treatment, not a quick fix.According to Rutgers University Camden, most studies so far run only one to two years and show ten to fifteen percent weight loss, but also high discontinuation rates due to side effects or access problems. That raises big questions about sustainability, cost, and what it means for body image to live in an era where powerful appetite changing drugs are widely used.There is also breaking science beyond injectable Ozempic. Advisory Board reports that Novo Nordisk has developed an oral semaglutide pill that produced about sixteen and a half percent weight loss over sixty four weeks, similar to the injection, and has been submitted for approval. Eli Lilly is developing another pill, orforglipron, which led to about twelve percent weight loss in trials without strict food timing rules, making it potentially easier to take.Then there isn't just double, but triple hormone targeting on the horizon. Advisory Board and ABC News describe retatrutide, sometimes called the triple G drug, which mimics three gut hormones. In early trials, people on the highest dose lost around twenty four to almost twenty nine percent of their body weight in about a year to sixteen months, and those with knee arthritis also reported large reductions in pain. These drugs are not yet approved, but multiple large phase three trials are underway.At the same time, researchers in Sweden, writing in the journal Cell and reported by outlets like Fox News and Prevention, are testing a completely different approach, an oral drug sometimes called ATR two five eight that acts more like exercise in a pill. Instead of mainly reducing appetite like Ozempic, it boosts muscle metabolism, improves blood sugar, increases fat burning, and seems to preserve muscle mass, at least in early animal and phase one human studies. If future trials confirm this, it could be combined with glucagon like peptide one drugs to protect muscle while enhancing weight loss.There may even be brain benefits. Science Daily recently covered an analysis suggesting that people with type two diabetes using glucagon like peptide one medicines such as Ozempic, Trulicity, or Victoza were less likely to develop epilepsy, hinting that these drugs might have protective effects in the brain. That research is still emerging, but it adds to ongoing studies on dementia, stroke, and other neurologic conditions.So where does all of this leave you as a listener trying to make sense of the Ozempic era? The evidence shows that semaglutide and related medicines can deliver double digit percentage weight loss, improve blood sugar, and reduce some obesity related risks. But they can cause side effects, are often expensive, and may need to be taken long term to keep the weight off. New pills and next generation drugs promise more convenience, more weight loss, and possibly fewer trade offs like muscle loss, yet they also raise fresh questions about safety, access, and how these medicines will change daily life, from what and how we eat to how we think about our bodies.On future episodes of Ozempic Weightloss Unlocked, we will dive deeper into personal stories, long term safety data, mental health, and practical tips for living well on these medicines, or deciding when they are not the right fit.Thank you for tuning in, and please remember to subscribe so you never miss an update on this fast moving world of Ozempic and weight loss science.This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Atrévete (Tramo de 06:00 a 07:00)

Atrévete (Tramo de 07:00 a 08:00)

Atrévete (Tramo de 08:00 a 09:00)

Atrévete (Tramo de 09:00 a 10:00)

En este episodio platicamos con la Gerente de producto de la marca Lynk & Co, con quien viajamos a China para conocer más de cerca, es una marca automotriz chino-sueca fundada en 2016, resultado de una colaboración entre Geely Auto Group y Volvo Car Group. Su objetivo es crear vehículos innovadores y de alta calidad, combinando la tecnología y seguridad de Volvo con la innovación y diseño chino. Utiliza la plataforma CMA (Compact Modular Architecture), desarrollada conjuntamente con Volvo, que permite una mayor flexibilidad y eficiencia en la producción. Impresionante lo que la marca Lynk & Co ha sido capaz de lograr en tan solo 9 años y han logrado vender 1.62 millones de unidades. Atrévete a conocer más sobre esta marca que seguramente te llamara la atención de inmediato por su tecnología y diseño. 

María creyó antes de ver. Su fe se adelantó nueve meses a la evidencia. Sin embargo, muchos esperan ver resultados antes de confiar, cuando la fe bíblica siempre da el primer paso sin garantías visibles. De modo que hoy sigue el ejemplo de esta joven que, sin entenderlo todo, dijo: “Hágase conmigo conforme a tu palabra”. Además, la fe que se adelanta al milagro no es impulsiva; es obediente. Surge en corazones que escuchan, se rinden y responden sin exigir explicaciones. Así pues, piensa en una área de tu vida donde Dios te está llamando a confiar antes de ver: una relación que necesita restauración, una decisión que requiere valentía o un sueño que parece imposible. Atrévete a creer antes del resultado. Los milagros suelen comenzar con un “sí” que honra a Dios más que a la lógica visible. La Biblia dice en Lucas 1:45: “Bienaventurada la que creyó, porque se cumplirá lo que le fue dicho de parte del Señor”. (RV1960).

En este podcast, escuchamos el debut de Violet Grohl -hija de Dave Grohl- y también a Tomora, nueva aventura de Tom Rowlands, de The Chemical Brothers, y Aurora. Aparte, escuchamos a Audrey Hobert, a Guv, a Channel Tres y a Ruthven-. XOEL LÓPEZ - Sombras ChinasCAROLINA DURANTE - Joderse La VidaBARRY B, CAROLINA DURANTE - Yo Pensaba Que Me Había Tocado DiosALCALÁ NORTE - SupermanCAMELLOS - CamónLEIVA, ROBE - Caída LibreEXTREMODURO - La Vereda de la Puerta de AtrásAUDREY HOBERT – Sex and the CityGUV - Warmer Than GoldVIOLET GROHL - ThumFOO FIGHTERS - The BestRUTHVEN - Precognition AMBER MARK ft ANDERSON.PAAK - Don't Remind MeCHANNEL TRES - En Vogue - Free Your MindTOMORA - Ring The AlarmROSALÍA - PorcelanaROBYN - Dopamine (Jamie xx Remix)Escuchar audio

Are you looking to save time, make money, and start winning with less risk? Then head to https://www.ovtlyr.com.If you have ever wondered why so many traders get crushed trading options, this breakdown will hit hard. In this video, we walk through a real conversation about the truth behind options trading, why most retail traders struggle, and how a smarter, data-driven approach can tilt the odds in your favor. There are wild stories here, from someone turning 88,000 dollars into 415 million only to lose it all, to the hard reality that over 75 percent of option trades lose money for most people. It is intense, but also eye opening.This isn't just a warning. It is a deep dive into the difference between gambling disguised as trading and actually having a systematic plan that gives you a real edge. You will see why embedded leverage can be both powerful and dangerous, how retail behavior resembles a casino more than an investment strategy, and what it actually takes to flip the script. If you have been treating options like a video game or chasing hype trades, this is the reality check you need.And yes, OVTLYR University comes up a lot because the whole point is helping traders shortcut the painful learning curve. When you understand risk, expectancy, and what real planning looks like, everything changes. You stop acting like a gambler and start acting like someone with a repeatable framework for wealth building.Here are a few standout moments from the video:✅ Why a 70 percent win rate can still destroy a trading account✅ How expectancy actually determines long term success✅ The real reason retail traders blow up accounts within 90 days✅ What systematic, backtested rules look like in practice✅ Why complex multi leg strategies often have negative expectancyThe conversation gets into hedging, bid ask spreads, expectancy math, backtesting insights, and even how emotional cycles like euphoria and denial trap most traders into buying at the top and panic selling at the bottom. You'll also hear a candid breakdown of strategies that seem smart but fail in real life, like iron condors with high win rates that still lead to massive losses. The honesty here is refreshing, especially compared to the hype driven content that floods the internet.This video also touches on the reality of watching successful traders online. Seeing someone win can trick you into taking more risk without understanding the downside. But when you have a real trading plan, you learn how to enter, exit, size your position, and respond to volatility instead of reacting emotionally. The message is simple: trading should be boring. If it feels exciting, you are probably doing something wrong.There is also a practical section showing how to use ATR, how to roll positions correctly, how to manage order blocks, and how to avoid adding unnecessary risk. These are the small details that separate consistent traders from the crowd that keeps blowing up accounts.If you want a smarter, more disciplined way to approach options trading, this walkthrough is going to help you see exactly where most people go wrong and how you can avoid the same traps.Gain instant access to the AI-powered tools and behavioral insights top traders use to spot big moves before the crowd. Start trading smarter today

Are you looking to save time, make money, and start winning with less risk? Then head to https://www.ovtlyr.com.Trades like this are the kind you remember. You put the position on, follow the plan, and it just takes off. In this OVTLYR Trading Room session, you get a front row seat to exactly how those trades unfolded, why the rolls were taken, how the risk was cut, and what signals kept everything on track. It's real trading in real time, and nothing is sugarcoated.One of the biggest takeaways in this session is how much clarity you gain when you stop stressing over your starting balance and start measuring your performance the right way. Money weighted returns finally make the math match reality, especially when your account has deposits, withdrawals, or both. When the numbers suddenly make sense, everything gets easier.On top of that, the video breaks down how OVTLYR plans operate in fast markets, calm markets, and everything in between. Rolling winners, managing open risk, knowing exactly when not to touch a trade, and using ATR levels to stay grounded are all on full display. And the best part is how simple it becomes once you understand the logic behind every move.Here's a quick snapshot of what you'll pick up:✅ How rolling trims risk while keeping winners alive✅ Why money weighted returns give a more accurate picture of your performance✅ How OVTLYR signals cut out the guesswork most traders struggle with✅ What to look for in trend strength, sector breadth, and order blocks✅ Why a rules-based plan removes stress from red candles and intraday noiseYou'll see trades that have already taken off 40 percent, 50 percent, even 74 percent of their risk, all while staying on because the trend is still holding. You'll also see why liquidity matters when rolling, how extrinsic value influences timing, and how sector confirmation sets the stage for new setups.The conversation also gets into the excitement building around the US Investing Championship and why having a real plan matters more than talking big online. Nothing beats transparent execution backed by data, and that theme carries throughout the entire session.By the end, you'll understand why calm, consistent execution beats hype every single time. You'll see how market breadth, fear and greed levels, and sector strength tell you when conditions are right for new trades. And you'll understand how pro traders think about capital, especially when only a small percentage is available for new opportunities.If you're serious about saving time, making money, and actually winning with less risk, this breakdown shows you exactly how the process works inside the OVTLYR Trading Room. Subscribe so you don't miss the next live session and keep building the skills that separate confident traders from emotional ones.Gain instant access to the AI-powered tools and behavioral insights top traders use to spot big moves before the crowd. Start trading smarter today